Hormone therapy and the cardiovascular system: The critical role of progestins

Climacteric

Volumn 6, Issue SUPPL. 3, 2003, Pages 21-28

  Sitruk Ware, R L ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b POPULATION COUNCIL   (United States)

Author keywords

Cardiovascular disease; Hormone replacement therapy; Progestins; Women's Health Initiative

Indexed keywords

ANDROGEN; ANTIANDROGEN; CONJUGATED ESTROGEN; DIENOGEST; DROSPIRENONE; ELCOMETRINE; ESTROGEN; GESTAGEN; GLUCOCORTICOID; MEDROXYPROGESTERONE ACETATE; MINERALOCORTICOID; MINERALOCORTICOID ANTAGONIST; NOMEGESTROL ACETATE; PROGESTERONE; TRIMEGESTONE;

BREAST CARCINOMA; CANCER INVASION; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONFERENCE PAPER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; HIP FRACTURE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; STROKE; VENOUS THROMBOEMBOLISM;

ANIMALS; CARDIOVASCULAR SYSTEM; CONTRACEPTIVE AGENTS, FEMALE; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MODELS, ANIMAL; PROGESTINS; RISK FACTORS;

EID: 1642538421     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease and other considerations. Ann Rev Public Health 1998;19:55-72
2. Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;99:821-8
3. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998;280:605-13
4. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000;343:522-9
5. Schulman SP, Thiemann DR, Ouyang P, et al. Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina. J Am Coll Cardiol 2002;39:231-7
6. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33
7. Regitz-Zagrosek V. Cardiovascular disease in postmenopausal women. Climacteric 2003;6(Suppl 3):13-20
8. Sitruk-Ware R. Progestins and cardiovascular risk markers. Steroids 2000;65:651-8
9. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-10
10. Ylikorkala O, Cacciatore B, Paakkari I, Tikkanen MJ, Viinikka L, Toivonen J. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane. Fertil Steril 1998;69:883-8
11. Williams AK, Honore EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994;24:1757-61
12. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998;83:721-6
13. Powers MS, Schenkel L, Darley PE, et al. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta estradiol: comparison with conventional oral estrogen used for hormone replacement. Am J Obstet Gynecol 1985;152:1099-106
14. Yen SSC, Martin PL, Burnier AM, Czekala NM, Greney MO Jr, Callantine MR. Circulating estradiol, estrone and gonadotropin levels following the administration of orally active 17β-estradiol in postmenopausal women. J Clin Endocrinol Metab 1975;40:518-20
15. Clarkson TB, Anthony MS, Klein KP. Hormone replacement therapy and coronary artery atherosclerosis: the monkey model. Br J Obstet Gynaecol 1996;103(Suppl 13):53-7
16. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-7
17. Clarkson TB, Anthony MS, Wagner JD. A comparison of tibolone and conjugated estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab 2001;86:5396-404
18. Williams JK, Delansorne R, Paris J. Estrogens, progestins, and coronary artery reactivity in atherosclerotic monkeys. J Steroid Biochem Mol Biol 1998;65:219-24
19. Rosano GMC, Chierchia SL, Morgani GL, Gabriele M, Leonardo F, Sarrel PM, Collins P. Effect of the association of different progestogens to estradiol 17β therapy upon effort-induced myocardial ischemia in female patients with coronary artery disease. J Am Coll Cardiol 1997;344A:Abstract 1028-1167
20. Bullock LP, Bardin CW. Androgenic, synandrogenic, and antiandrogenic actions of progestins. Ann NY Acad Sci 1977;286:321-30
21. Kumar N, Koide SS, Tsong YY, Sundaram K. Nestorone®: a progestin with a unique pharmacological profile. Steroids 2000;65:629-36
22. Philibert D, Bouchoux F, Degryse D, Lecaque D, Petit F, Gaillard M. The pharmacological profile of a novel norpregnane progestin (trimegestone). Gynecol Endocrinol 1999;13:316-26
23. Paris J, Thevenot R, Bonnet P, Granero M. The pharmacological profile of TX 066 (17α-acetoxy-6methyl-19-nor-4, 6-pregna-diene-3, 20-dione), a new oral progestative. Drug Res 1983;33:710-15
24. Bullock LP, Bardin CW. Androgenic, synandrogenic, and antiandrogenic actions of progestins. Ann NY Acad Sci 1977;286:321-30
25. Duc I, Botella J, Bonnet P, Fraboul F, Delansome R, Paris J. Antiandrogenic properties of nomegestrol acetate. Arzneim Forsch/Drug Res 1995;45:70-4
26. Oettel M, Graser T, Hoffman H. Why dienogest as a progestagenic component of postmenopausal nonandrogenic hormone replacement therapy. Drugs Today 2001;37(Suppl G):3-15
27. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38
28. Brache V, Massai R, Mishell DR, et al. Ovarian function during use of Nestorone subdermal implants. Contraception 2000;61:199-204
29. Godsland I. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein(a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898-915
30. Shenfield GM, Griffin JM. Clinical pharmacokinetics of contraceptive steroids. An update. Clin Pharmacokinet 1991;20:15-37
31. Dusterberg B, Humpel M, Speck U. Terminal half-lives in plasma and bioavailability of norethisterone, levonorgestrel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys. Contraception 1981;24:673-83
32. Noe G, Salvatierra A, Heikinheimo O, Maturana X, Croxatto HB. Pharmacokinetics and bioavailability of ST 1435 administered by different routes. Contraception 1993;48:548-56